Jpmorgan Chase & CO Curis Inc Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.51 - $0.78 $969 - $1,482	-1,900 Reduced 47.03%	2,140 $1,000
Q4 2022 Feb 13, 2023	SELL	$0.47 - $17.22 $854 - $31,305	-1,818 Reduced 31.03%	4,040 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $1,357 - $27,543	1,835 Added 45.61%	5,858 $4,000
Q2 2022 Aug 11, 2022	SELL	$0.71 - $2.43 $222,482 - $761,455	-313,356 Reduced 98.73%	4,023 $4,000
Q1 2022 May 11, 2022	BUY	$2.31 - $5.13 $636,190 - $1.41 Million	275,407 Added 656.17%	317,379 $756,000
Q4 2021 Feb 10, 2022	BUY	$4.45 - $8.09 $42,849 - $77,898	9,629 Added 29.77%	41,972 $199,000
Q3 2021 Nov 12, 2021	BUY	$6.94 - $8.85 $224,460 - $286,235	32,343 New	32,343 $253,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $403M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.